Deals in Depth: December 2010
Executive Summary
Cephalon's $2.1 billion alliance with Mesoblast for adult mesenchymal precursor stem cells was not only the largest-valued alliance of December, but also the biggest of 2010. M&As in the research tools and diagnostics markets brought in huge numbers including Thermo's $2.1 billion acquisition of Dionex. Publicly raised biopharma money totaled $2.6 billion, thanks to Otsuka's massive IPO. But medical device public fundraising decreased 40% to $148 million.